Evidence map›Paper›PMID 28796934›Full record

Trial reportCardiovascular therapeutics2017

Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease.

So-Ryoung Lee, In-Ho Chae, Hack-Lyoung Kim, Do-Yoon Kang, Sang-Hyun Kim, Hyo-Soo Kim

Open access · hybridAbstract readClinical Trial, Phase IVMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

So-Ryoung LeeDivision of Cardiology, Department of Internal Medicine/Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.
In-Ho ChaeDepartment of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea.
Hack-Lyoung KimDivision of Cardiology, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.
Do-Yoon KangDivision of Cardiology, Department of Internal Medicine/Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.
Sang-Hyun KimDivision of Cardiology, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.
Hyo-Soo KimDivision of Cardiology, Department of Internal Medicine/Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.ORCID http://orcid.org/0000-0003-0847-5329
Seoul National University · KRSeoul National University Bundang Hospital · KRSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

aimsEndothelial dysfunction and arterial stiffness have a prognostic value on adverse long-term outcomes in coronary artery disease (CAD) patients. We evaluated the efficacy on vascular reactivity of candesartan and analyzed predictors to control the candesartan's effect on vascular reactivity in CAD patients.

methodPatients were prospectively enrolled and prescribed candesartan for 6 months. The effect on vascular reactivity was evaluated by the change in flow-mediated dilation (FMD) and pulse wave velocity (PWV).

resultsA total of 124 patients completed the study. The better responder in FMD change (≥1.3%) showed significantly lower baseline FMD than the poor responder (P < .001). In receiver operating characteristic analysis, baseline FMD 7.5% showed optimal predictive value (sensitivity 79%, specificity 79%) for predicting better responder. The baseline endothelial dysfunction (FMD <7.5%) was the only significant predictor of the better responder to candesartan. The better responder in PWV change (≤-100 cm/s) showed greater blood pressure lowering and significantly higher baseline PWV than the poor responder (both P < .05). The poor responder in both FMD and PWV showed a higher prevalence of previous myocardial infarction (38.7% vs 17.2%, P = .013).

conclusionThe candesartan's effect on vascular reactivity is more pronounced in patients with more severe endothelial dysfunction and arterial stiffness. Poor responders on both FMD and PWV showed higher prevalence of previous myocardial infarction.

Indexed as

AgedAngiotensin II Type 1 Receptor BlockersBenzimidazolesBiphenyl CompoundsBrachial ArteryCoronary Artery DiseaseCoronary StenosisFemaleHumansMaleMiddle AgedMyocardial InfarctionPrevalenceProspective StudiesPulse Wave AnalysisSeoulAngiotensin II Type 1 Receptor BlockersBenzimidazolesBiphenyl CompoundscandesartanTetrazolesAngiotensin II type 1 receptor blockersArterial stiffnessEndothelial dysfunctionFlow-mediated dilationPulse wave velocity

Identifiers

PMID28796934
PMCPMC5639377
OpenAlexW2743281864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.